Author

E. W. Weber

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 5 Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 3 Approach:genetic perturbation / CRISPR· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Assay:CITE-seq· 2

Frequent Co-Authors

C. L. Mackall· 4 shared E. Sotillo· 3 shared P. Xu· 3 shared A. T. Satpathy· 2 shared H. Anbunathan· 2 shared H. Y. Chang· 2 shared M. Malipatlolla· 2 shared R. C. Lynn· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

C. L. Mackall

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

TET2 regulates early and late transitions in exhausted CD8+ T-cell differentiation and limits CAR T-cell function

A. J. Dimitri, A. E. Baxter, G. M. Chen, C. R. Hopkins, G. T. Rouin, H. Huang, W. Kong, C. H. Holliday, V. Wiebking, R. Bartoszek, S. Drury, K. Dalton, O. M. Koucky, Z. Chen, J. R. Giles, , J. A. Fraietta

This study shows that targeting TET2 in CAR T-cells improves their anti-tumor responses by limiting terminal exhaustion and enhancing therapeutic potential.

bioRxiv · Mar 29, 2024Immunology

Transient EZH2 suppression by Tazemetostat during in vitro expansion maintains T cell stemness and improves adoptive T cell therapy

Y. Hou, J. Zak, Y. Shi, I. Pratumchai, B. Dinner, W. Wang, K. Qin, E. W. Weber, J. Teijaro, P. Wu

The paper shows that transient EZH2 inhibition with Tazemetostat during T cell expansion maintains stemness and improves adoptive T cell therapy outcomes in a murine model.

bioRxiv · Feb 7, 2023 · PreprintImmunology

Enhanced Effector Activity of Mediator Kinase Module Deficient CAR-T Cells

K. A. Freitas, J. A. Belk, E. Sotillo, B. Daniel, K. Sandor, D. Klysz, V. T. Duong, K. A. Burdsall, P. Xu, M. Malipatlolla, M. G. Donovan, E. W. Weber, R. G. Majzner, H. Y. Chang, J. M. Espinosa, , C. L. Mackall

This study identifies the Mediator kinase module as a regulator of T cell differentiation and shows that its inhibition enhances effector T cell potency.

bioRxiv · Sep 2, 2022 · PreprintImmunology

Repeated stimulation or tonic-signaling chimeric antigen receptors drive regulatory T cell exhaustion

C. Lamarche, G. Novakovsky, C. N. Qi, E. W. Weber, C. L. Mackall, M. K. Levings

This study shows that human regulatory T cells (Tregs) can become exhausted through repetitive stimulation or tonic-signaling CARs, reducing their suppressive function in vivo.

bioRxiv · Jun 27, 2020 · PreprintImmunology

Transient "rest" induces functional reinvigoration and epigenetic remodeling in exhausted CAR-T cells

E. W. Weber, R. C. Lynn, K. R. Parker, H. Anbunathan, J. Lattin, E. Sotillo, Z. Good, M. Malipatlolla, P. Xu, P. Vandris, R. G. Majzner, Y. Qi, L.-C. Chen, A. J. Gentles, T. J. Wandless, , C. L. Mackall

This study shows that temporarily stopping CAR-T cell signaling can reverse exhaustion and improve their anti-tumor function through transcriptional and epigenetic changes.

bioRxiv · Jan 26, 2020 · PreprintImmunology

c-Jun Overexpressing CAR-T Cells are Exhaustion-Resistant and Mediate Enhanced Antitumor Activity

R. C. Lynn, E. W. Weber, D. Gennert, E. Sotillo, P. Xu, Z. Good, H. Anbunathan, R. Jones, V. Tieu, J. Granja, C. DeBourcy, R. Majzner, A. Satpathy, S. R. Quake, H. Chang, C. L. Mackall

This study shows that overexpressing c-Jun in CAR-T cells reduces exhaustion and improves antitumor activity in vivo.

bioRxiv · May 29, 2019 · PreprintImmunology